Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.

about

ALK and ROS1 as a joint target for the treatment of lung cancer: a review

P2860

Q26851392-2EC5E262-C9D2-4033-9CAC-880716AC4E1D

P2860

Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.

Item

http://www.wikidata.org/entity/Q39252246

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Identification of novel anapla ...... ligands crystallized with ALK.

@en

Identification of novel anaplastic lymphoma kinase

@nl

type

Item

label

Identification of novel anapla ...... ligands crystallized with ALK.

@en

Identification of novel anaplastic lymphoma kinase

@nl

prefLabel

Identification of novel anapla ...... ligands crystallized with ALK.

@en

Identification of novel anaplastic lymphoma kinase

@nl

P1476

Identification of novel anapla ...... ligands crystallized with ALK.

@en

P2093

Hai Lan

http://www.w3.org/2001/XMLSchema#string

Huan-Zhang Xie

http://www.w3.org/2001/XMLSchema#string

Hui Zhang

http://www.w3.org/2001/XMLSchema#string

Jun Zou

http://www.w3.org/2001/XMLSchema#string

Lin-Li Li

http://www.w3.org/2001/XMLSchema#string

Qi Huang

http://www.w3.org/2001/XMLSchema#string

Sheng-Yong Yang

http://www.w3.org/2001/XMLSchema#string

You-Li Pan

http://www.w3.org/2001/XMLSchema#string

Ze-Rong Wang

http://www.w3.org/2001/XMLSchema#string

P2860

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Activating mutations in ALK provide a therapeutic target in neuroblastoma.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway

Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

P304

175-184

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CBDD.12084

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23107363

http://www.w3.org/2001/XMLSchema#string

Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.

about

P2860

P2860

Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698